Advanced Research in Hematological Malignancies
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 31 January 2027 | Viewed by 289
Editor
Special Issue Information
Dear Colleagues,
Hematological malignancies, encompassing leukemia, lymphoma, myeloma, and related disorders, represent a complex spectrum of diseases with evolving diagnostic, prognostic, and therapeutic landscapes. Despite advancements in molecular profiling, targeted therapies, and immunotherapies, significant challenges persist in improving patient outcomes, particularly for refractory or relapsed cases. This Special Issue aims to highlight cutting-edge research driving innovation in the understanding and management of hematologic cancers.
We invite original research articles, reviews, and perspectives that address critical areas such as molecular pathogenesis, novel biomarkers, precision medicine approaches, resistance mechanisms, and emerging therapeutic strategies (e.g., CAR-T cells, bispecific antibodies, and epigenetic modulators). Submissions exploring translational insights from preclinical models to clinical trials, as well as studies integrating multi-omics data or artificial intelligence for risk stratification, are particularly encouraged.
This issue seeks to foster interdisciplinary collaboration among researchers, clinicians, and translational scientists to accelerate progress in hematologic oncology. By disseminating high-impact findings, we aim to advance personalized treatment paradigms and address unmet clinical needs.
Dr. Te-Fu Weng
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hematological malignancies
- leukemia
- lymphoma
- myeloma
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
